Novo outlays $2.6bn in Hengrui deal to bolster oral obesity pipeline - Pharmaceutical Technology

Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena. Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena. Novo hopes that HRS-1596 could offer as a more convenient oral treatment option due to its once-weekly dosing schedule. Credit: Studio Romantic / Shutterstock.com. Novo has inked a licensing agreement with Shanghai-based biopharma, Hengrui Pharma for an oral metabolic disease candidate as the pharma titan looks to get a leg up on…

Source: Pharmaceutical Technology